Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study

被引:110
|
作者
Amabile, Nicolas [1 ,2 ]
Guerin, Alain P. [2 ,3 ]
Tedgui, Alain [1 ,2 ]
Boulanger, Chantal M. [1 ,2 ]
London, Gerard M. [1 ,2 ,3 ]
机构
[1] Paris Cardiovasc Res Ctr PARCC, INSERM, U970, Paris, France
[2] Univ Paris 05, UMR S970, Paris, France
[3] Ctr Hosp Manhes, Dept Nephrol, Fleury Merogis, France
关键词
endothelial dysfunction; endothelial microparticles; end-stage renal disease; microparticles; mortality; C-REACTIVE PROTEIN; CORONARY-ARTERY-DISEASE; HEMODIALYSIS-PATIENTS; ELEVATED LEVELS; KIDNEY-DISEASE; NITRIC-OXIDE; DYSFUNCTION; RISK; STIFFNESS; CORRELATE;
D O I
10.1093/ndt/gfr573
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Endothelial dysfunction in cardiovascular (CV) diseases is closely associated with increases in plasma level of shed membrane microparticles (MPs) of endothelial origin. As arterial damage is a major contributor to CV mortality, we examined whether or not increases in endothelial microparticles (EMPs) circulating levels could predict outcome in patients with end-stage renal disease (ESRD). Methods. This prospective pilot study conducted in a community hospital (median follow-up: 50.5 months), included 81 stable haemodialysed ESRD patients (59 +/- 14 years; 63% male). Platelet-free plasma obtained 72 h after last dialysis was analysed by flow cytometry, and MPs cellular origin identified as endothelial (CD31+CD41-MPs; EMPs), platelets (CD31+CD41-MPs) or erythrocyte (CD235a+MPs). The main outcome measures were global and CV mortality (fatal myocardial infarction, stroke, acute pulmonary oedema and sudden cardiac death). Results. Non-survivors (n = 24) were older (P < 0.001) and characterized by higher levels of EMPs (P < 0.01) and high-sensitivity C-reactive protein (P < 0.05) and lower diastolic blood pressure (P < 0.001). Kaplan-Meier analysis demonstrated significantly higher probability of all-cause (P < 0.001) and CV mortality (P < 0.0001) between the lower and upper EMPs tertiles. Multivariate Cox regression analysis demonstrated that baseline EMP levels independently predicted all-cause [hazard ratio (HR) = 21.7, 95% confidence interval (CI): 4.23-111.18 per log EMPs/mu L; P = 0.0002] and CV mortality (HR = 20.0, 95% CI: 3.86-103.5) per log EMPs/mu L; P < 0.0004) after adjustment for confounding factors. EMPs baseline level was a stronger predictor of poor outcome than classical risk factors. Conclusion. This study demonstrates that increased plasma levels of EMPs is a robust independent predictor of severe CV outcome in end-stage renal failure patients.
引用
收藏
页码:1873 / 1880
页数:8
相关论文
共 50 条
  • [41] Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease
    Pannier, B
    Guerin, AP
    Marchais, SJ
    Metivier, F
    Safar, ME
    London, GM
    KIDNEY INTERNATIONAL, 2000, 57 (03) : 1091 - 1099
  • [42] Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease
    Zoccali, C
    BLOOD PURIFICATION, 2002, 20 (05) : 469 - 472
  • [43] Circulating Endothelial Progenitor Cell Levels Predict Cardiovascular Events in End-Stage Renal Disease Patients on Maintenance Hemodialysis
    Lee, Hong Joo
    Kim, Weon
    Kim, Woo Shik
    Woo, Jong Shin
    Kim, Yang Gyoon
    Moon, Ju Young
    Lee, Sang Ho
    Ihm, Chun Gyoo
    Lee, Tae Won
    Jeong, Kyung Hwan
    NEPHRON, 2015, 130 (03) : 151 - 158
  • [44] Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD)
    Zoccali, C
    Mallamaci, F
    Tripepi, G
    Parlongo, S
    Cutrupi, S
    Benedetto, FA
    Bonanno, G
    Seminara, G
    Fatuzzo, P
    Rapisarda, F
    Malatino, LS
    KIDNEY INTERNATIONAL, 2003, 64 (02) : 579 - 584
  • [45] The Predictive Value of the SIPAT for clinical Outcomes in End-Stage Heart Failure Candidates
    Grogan, S. D.
    Bruce, C. R.
    Cordero-Reyes, A. M.
    Soliman, A.
    Estep, J. D.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (04): : S107 - S107
  • [46] Predictive value of cytokine gene polymorphisms for the development of end-stage renal disease
    Babel, Nina
    Gabdrakhmanova, Leila
    Hammer, Markus H.
    Schoenemann, Constanze
    Skrypnikov, Volodimir
    Poliak, Nina
    Volk, Hans-Dieter
    Reinke, Petra
    JOURNAL OF NEPHROLOGY, 2006, 19 (06) : 802 - 807
  • [47] Reducing cardiovascular morbidity and mortality from hypertension in end-stage renal disease
    Picton, ML
    Foley, RN
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2000, 9 (05): : 497 - 500
  • [48] Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease
    Shoji, T
    Emoto, M
    Shinohara, K
    Kakiya, R
    Tsujimoto, K
    Kishimoto, H
    Ishimura, E
    Tabata, T
    Nishizawa, Y
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2001, 12 (10): : 2117 - 2124
  • [49] Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease
    Buccianti, G
    Baragetti, I
    Bamonti, F
    Furiani, S
    Dorighet, V
    Patrosso, C
    JOURNAL OF NEPHROLOGY, 2004, 17 (03) : 405 - 410
  • [50] Midkine release during hemodialysis is predictive of hypervolemia and associates with excess (cardiovascular) mortality in patients with end-stage renal disease: a prospective study
    Brandt, Sabine
    Fischer, Anja
    Kreutze, Carla
    Hempel, Dorothea
    Gorny, Xenia
    Scurt, Florian G.
    Balaru, Delia L.
    Bartsch, Peter
    Bernhardt, Anja
    Bode-Boeger, Stefanie M.
    Girndt, Matthias
    Fiedler, Roman
    Isermann, Berend
    Lindquist, Jonathan A.
    Mertens, Peter R.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (09) : 2407 - 2420